Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3634MR)

This product GTTS-WQ3634MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3634MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10550MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ10763MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ8729MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4346MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ2104MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ13359MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1178MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ3258MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW